REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors

DOI10.1002/SIM.10107zbMATH Open1545.62663MaRDI QIDQ6618357

Evan Kwiatkowski, Young Jack Lee, Ruitao Lin, Author name not available (Why is that?)

Publication date: 14 October 2024

Published in: Statistics in Medicine (Search for Journal in Brave)

zbMATH Keywords

Bayesian methodsmeta-analysisspike-and-slab priorphase I/II trialdose optimization

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• Title not available (Why is that?)
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials
• Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors
• Group up-and-down designs for dose-finding
• Design and Analysis of Phase I Clinical Trials
• Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
• Determining the Effective Sample Size of a Parametric Prior
• A Bayesian Phase I/II Trial Design for Immunotherapy
• A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
• Change-point joint model for identification of plateau of activity in early phase trials
• Bayesian optimal interval designs for phase I clinical trials
• Phase I--II trial design for biologic agents using conditional auto-regressive models for toxicity and efficacy
• An information theoretic phase I--II design for molecularly targeted agents that does not require an assumption of monotonicity

This page was built for publication: REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6618357)